Safety and Efficacy of BFH772 in Psoriasis Patients

NCT00987870 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-03-28

No results posted yet for this study

Summary

This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.

Conditions

Interventions

DRUG

BFH772

DRUG

Placebo

DRUG

BFH772

DRUG

Placebo

DRUG

calcipotriol/betamethasone

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987870 on ClinicalTrials.gov